Neurodegeneration in the pathogenesis of diabetic retinopathy: Molecular mechanisms and therapeutic implications

Current Medicinal Chemistry

Volumn 20, Issue 26, 2013, Pages 3241-3250

  Stem, Maxwell S ^a   Gardner, Thomas W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Diabetes; Diabetic retinopathy; Mechanisms; Neurodegeneration; Neurovascular; Pathogenesis; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; APOPTOSIS INHIBITOR; BRAIN DERIVED NEUROTROPHIC FACTOR; BROMFENAC; DOPAMINE; DOXYCYCLINE; ERYTHROPOIETIN; ETANERCEPT; GLUCAGON; GLUTAMATE AMMONIA LIGASE; GLYCINE; HEMOGLOBIN A1C; INFLIXIMAB; INSULIN; INTERLEUKIN 1BETA; LATANOPROST; MEMANTINE; MINOCYCLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROTROPHIN; PHLORIZIN; PROLACTIN; RUBOXISTAURIN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CATARACT EXTRACTION; CELL JUNCTION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; ELECTRORETINOGRAM; EXCITOTOXICITY; GLIA CELL; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INNATE IMMUNITY; INSULIN DEFICIENCY; LEUKOSTASIS; LOW DRUG DOSE; METABOLIC DISORDER; METABOLIC REGULATION; MICROGLIA; MOLECULAR PATHOLOGY; NEOVASCULARIZATION (PATHOLOGY); NERVE CELL; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OPTICAL COHERENCE TOMOGRAPHY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROLIFERATIVE RETINOPATHY; RETINA NERVE CELL; RETINAL THICKNESS; VASODILATATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANIMALS; DIABETIC RETINOPATHY; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEURODEGENERATIVE DISEASES;

EID: 84883231913     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990027     Document Type: Article

References (132)

1. Aiello, L. M. Perspectives on diabetic retinopathy. Am. J. Ophthalmol., 2003, 136(1), 122-135.
2. Wilkinson, C. P.; Ferris, F. L., 3rd; Klein, R. E.; Lee, P. P.; Agardh, C. D.; Davis, M.; Dills, D.; Kampik, A.; Pararajasegaram, R.; Verdaguer, J. T. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology, 2003, 110(9), 1677-1682.
3. Wolter, J. R. Diabetic retinopathy. Am. J. Ophthalmol., 1961, 51, 1123-1141.
4. Bloodworth, J. M., Jr. Diabetic retinopathy. Diabetes, 1962, 11, 1-22.
5. Cunha-Vaz, J. Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, randomised controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest Diabetic Retinopathy. EUROCONDOR - EU FP7 Project. Acta Ophthalmol., 2012, 90(249), 0.
6. Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am. J. Ophthalmol., 1976, 81(4), 383-396.
7. Doft, B. H.; Blankenship, G. W. Single versus multiple treatment sessions of argon laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology, 1982, 89(7), 772-779.
8. Pahor, D. Visual field loss after argon laser panretinal photocoagulation in diabetic retinopathy: full-versus mild-scatter coagulation. Int. Ophthalmol., 1998, 22(5), 313-319.
9. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology, 1991, 98(5), 766-785.
10. Seiberth, V.; Alexandridis, E.; Feng, W. Function of the diabetic retina after panretinal argon laser coagulation. Graefes Arch. Clin. Exp. Ophthalmol., 1987, 225(6), 385-390.
11. Russell, P. W.; Sekuler, R.; Fetkenhour, C. Visual function after pan-retinal photocoagulation: a survey. Diabetes Care, 1985, 8(1), 57-63.
12. Pender, P. M.; Benson, W. E.; Compton, H.; Cox, G. B. The effects of panretinal photocoagulation on dark adaptation in diabetics with proliferative retinopathy. Ophthalmology, 1981, 88(7), 635-638.
13. Nguyen, Q. D.; Shah, S. M.; Heier, J. S.; Do, D. V.; Lim, J.; Boyer, D.; Abraham, P.; Campochiaro, P. A. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology, 2009, 116(11), 2175-2181 e1.
14. Nguyen, Q. D.; Brown, D. M.; Marcus, D. M.; Boyer, D. S.; Patel, S.; Feiner, L.; Gibson, A.; Sy, J.; Rundle, A. C.; Hopkins, J. J.; Rubio, R. G.; Ehrlich, J. S. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology, 2012, 119(4), 789-801.
15. Mitchell, P.; Bandello, F.; Schmidt-Erfurth, U.; Lang, G. E.; Massin, P.; Schlingemann, R. O.; Sutter, F.; Simader, C.; Burian, G.; Gerstner, O.; Weichselberger, A. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology, 2011, 118(4), 615-625.
16. Simo, R.; Hernandez, C. Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br. J. Ophthalmol., 2012, 96(10), 1285-1290.
17. Metea, M. R.; Newman, E. A. Signalling within the neurovascular unit in the mammalian retina. Exp. Physiol. 2007, 92(4), 635-640.
18. Kur, J.; Newman, E. A.; Chan-Ling, T. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. Prog. Retin. Eye Res., 2012, 31(5), 377-406.
19. Petzold, G. C.; Murthy, V. N. Role of astrocytes in neurovascular coupling. Neuron, 2011, 71(5), 782-797.
20. Schafer, D. P.; Lehrman, E. K.; Kautzman, A. G.; Koyama, R.; Mardinly, A. R.; Yamasaki, R.; Ransohoff, R. M.; Greenberg, M. E.; Barres, B. A.; Stevens, B. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron, 2012, 74(4), 691-705.
21. Volgyi, B.; Kovacs-Oller, T.; Atlasz, T.; Wilhelm, M.; Gabriel, R. Gap junctional coupling in the vertebrate retina: Variations on one theme? Prog. Retin. Eye Res., 2013.
22. Runkle, E. A.; Antonetti, D. A. The blood-retinal barrier: structure and functional significance. Methods Mol. Biol., 2011, 686, 133-148.
23. del Zoppo, G. J. The neurovascular unit in the setting of stroke. J. Intern. Med., 2010, 267(2), 156-171.
24. Zlokovic, B. V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron, 2008, 57(2), 178-201.
25. Lott, M. E.; Slocomb, J. E.; Shivkumar, V.; Smith, B.; Gabbay, R. A.; Quillen, D.; Gardner, T. W.; Bettermann, K. Comparison of retinal vasodilator and constrictor responses in type 2 diabetes. Acta Ophthalmol., 2012, 90(6), e434-441.
26. Bek, T.; Hajari, J.; Jeppesen, P. Interaction between flicker-induced vasodilatation and pressure autoregulation in early retinopathy of type 2 diabetes. Graefes Arch. Clin. Exp. Ophthalmol., 2008, 246(5), 763-769.
27. Garhofer, G.; Zawinka, C.; Resch, H.; Kothy, P.; Schmetterer, L.; Dorner, G. T. Reduced response of retinal vessel diameters to flicker stimulation in patients with diabetes. Br. J. Ophthalmol., 2004, 88(7), 887-891.
28. Lasta, M.; Pemp, B.; Schmidl, D.; Boltz, A.; Kaya, S.; Palkovits, S.; Werkmeister, R.; Howorka, K.; Popa-Cherecheanu, A.; Garhofer, G.; Schmetterer, L. Neurovascular dysfunction precedes neural dysfunction in the retina of patients with type 1 diabetes. Invest. Ophthalmol. Vis. Sci., 2013.
29. Antonetti, D. A.; Klein, R.; Gardner, T. W. Diabetic retinopathy. N. Engl. J. Med., 2012, 366(13), 1227-1239.
30. Harrison, W. W.; Bearse, M. A., Jr.; Ng, J. S.; Jewell, N. P.; Barez, S.; Burger, D.; Schneck, M. E.; Adams, A. J. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest. Ophthalmol. Vis. Sci., 2011, 52(2), 772-777.
31. Ng, J. S.; Bearse, M. A., Jr.; Schneck, M. E.; Barez, S.; Adams, A. J. Local diabetic retinopathy prediction by multifocal ERG delays over 3 years. Invest. Ophthalmol. Vis. Sci., 2008, 49(4), 1622-1628.
32. Gualtieri, M.; Bandeira, M.; Hamer, R. D.; Damico, F. M.; Moura, A. L.; Ventura, D. F. Contrast sensitivity mediated by inferred magno-and parvocellular pathways in type 2 diabetics with and without nonproliferative retinopathy. Invest. Ophthalmol. Vis. Sci., 2011, 52(2), 1151-1155.
33. Greenstein, V. C.; Thomas, S. R.; Blaustein, H.; Koenig, K.; Carr, R. E. Effects of early diabetic retinopathy on rod system sensitivity. Optom. Vis. Sci., 1993, 70(1), 18-23.
34. Jackson, G. R.; Scott, I. U.; Quillen, D. A.; Walter, L. E.; Gardner, T. W. Inner retinal visual dysfunction is a sensitive marker of nonproliferative diabetic retinopathy. Br. J. Ophthalmol., 2012, 96(5), 699-703.
35. Parravano, M.; Oddone, F.; Mineo, D.; Centofanti, M.; Borboni, P.; Lauro, R.; Tanga, L.; Manni, G. The role of Humphrey Matrix testing in the early diagnosis of retinopathy in type 1 diabetes. Br. J. Ophthalmol., 2008, 92(12), 1656-1660.
36. van Dijk, H. W.; Verbraak, F. D.; Kok, P. H.; Garvin, M. K.; Sonka, M.; Lee, K.; Devries, J. H.; Michels, R. P.; van Velthoven, M. E.; Schlingemann, R. O.; Abramoff, M. D. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest. Ophthalmol. Vis. Sci., 2010, 51(7), 3660-3665.
37. Park, H. Y.; Kim, I. T.; Park, C. K. Early diabetic changes in the nerve fibre layer at the macula detected by spectral domain optical coherence tomography. Br. J. Ophthalmol., 2011, 95(9), 1223-1228.
38. Antonetti, D. A.; Barber, A. J.; Bronson, S. K.; Freeman, W. M.; Gardner, T. W.; Jefferson, L. S.; Kester, M.; Kimball, S. R.; Krady, J. K.; LaNoue, K. F.; Norbury, C. C.; Quinn, P. G.; Sandirasegarane, L.; Simpson, I. A. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes, 2006, 5 (9), 2401-2411.
39. Sinclair, S. H.; Grunwald, J. E.; Riva, C. E.; Braunstein, S. N.; Nichols, C. W.; Schwartz, S. S. Retinal vascular autoregulation in diabetes mellitus. Ophthalmology, 1982, 89(7), 748-750.
40. Kylstra, J. A.; Wierzbicki, T.; Wolbarsht, M. L.; Landers, M. B., 3rd; Stefansson, E. The relationship between retinal vessel tortuosity, diameter, and transmural pressure. Graefes Arch. Clin. Exp. Ophthalmol., 1986, 224(5), 477-480.
41. Kristinsson, J. K.; Gottfredsdottir, M. S.; Stefansson, E. Retinal vessel dilatation and elongation precedes diabetic macular oedema. Br. J. Ophthalmol., 1997, 81(4), 274-278.
42. Umegaki, H. Neurodegeneration in diabetes mellitus. Adv. Exp. Med. Biol., 2012, 724, 258-265.
43. Reijmer, Y. D.; Brundel, M.; de Bresser, J.; Kappelle, L. J.; Leemans, A.; Biessels, G. J. Microstructural White Matter Abnormalities and Cognitive Functioning in Type 2 Diabetes: A diffusion tensor imaging study. Diabetes Care, 2013, 36(1), 137-144.
44. Gardner, T. W.; Abcouwer, S. F.; Barber, A. J.; Jackson, G. R. An integrated approach to diabetic retinopathy research. Arch. Ophthalmol., 2011, 129(2), 230-235.
45. Chang-Chen, K. J.; Mullur, R.; Bernal-Mizrachi, E. Beta-cell failure as a complication of diabetes. Rev. Endocr. Metab. Disord., 2008, 9(4), 329-343.
46. Nadeau, K. J.; Regensteiner, J. G.; Bauer, T. A.; Brown, M. S.; Dorosz, J. L.; Hull, A.; Zeitler, P.; Draznin, B.; Reusch, J. E. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J. Clin. Endocrinol. Metab., 2010, 95(2), 513-521.
47. Pambianco, G.; Costacou, T.; Orchard, T. J. The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care, 2007, 30(5), 1248-1254.
48. Rajala, R. V.; Anderson, R. E. Rhodopsin-regulated insulin receptor signaling pathway in rod photoreceptor neurons. Mol. Neurobiol., 2010, 42(1), 39-47.
49. Rajala, R. V. Phosphoinositide 3-kinase signaling in the vertebrate retina. J. Lipid Res., 2010, 51(1), 4-22.
50. Reiter, C. E.; Gardner, T. W. Functions of insulin and insulin receptor signaling in retina: possible implications for diabetic retinopathy. Prog. Retin. Eye Res., 2003, 22(4), 545-562.
51. Rajala, R. V.; McClellan, M. E.; Ash, J. D.; Anderson, R. E. In vivo regulation of phosphoinositide 3-kinase in retina through lightinduced tyrosine phosphorylation of the insulin receptor betasubunit. J. Biol. Chem., 2002, 277(45), 43319-43326.
52. Huang, Z.; Anderson, R. E.; Cao, W.; Wiechmann, A. F.; Rajala, R. V. Light-induced tyrosine phosphorylation of rod outer segment membrane proteins regulate the translocation, membrane binding and activation of type II alpha phosphatidylinositol-5-phosphate 4-kinase. Neurochem. Res., 2011, 36(4), 627-635.
53. Hammes, H. P.; Federoff, H. J.; Brownlee, M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol. Med., 1995, 1(5), 527-534.
54. Barber, A. J.; Lieth, E.; Khin, S. A.; Antonetti, D. A.; Buchanan, A. G.; Gardner, T. W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J. Clin. Invest., 1998, 102(4), 783-791.
55. Fort, P. E.; Losiewicz, M. K.; Reiter, C. E.; Singh, R. S.; Nakamura, M.; Abcouwer, S. F.; Barber, A. J.; Gardner, T. W. Differential roles of hyperglycemia and hypoinsulinemia in diabetes induced retinal cell death: evidence for retinal insulin resistance. PLoS One, 2011, 6(10), e26498.
56. Das Evcimen, N.; King, G. L. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol. Res., 2007, 55(6), 498-510.
57. Way, K. J.; Katai, N.; King, G. L. Protein kinase C and the development of diabetic vascular complications. Diabet. Med., 2001, 18(12), 945-959.
58. Aiello, L. P.; Vignati, L.; Sheetz, M. J.; Zhi, X.; Girach, A.; Davis, M. D.; Wolka, A. M.; Shahri, N.; Milton, R. C. Oral protein kinase c beta inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study 2. Retina, 2011, 31(10), 2084-2094.
59. Zong, H.; Ward, M.; Stitt, A. W. AGEs, RAGE, and diabetic retinopathy. Curr. Diabetes Rep., 2011, 11(4), 244-252.
60. Suzen, S.; Buyukbingol, E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr. Med. Chem., 2003, 10(15), 1329-1352.
61. Madsen-Bouterse, S. A.; Kowluru, R. A. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev. Endocr. Metab. Disord., 2008, 9(4), 315-327.
62. Silva, K. C.; Rosales, M. A.; Biswas, S. K.; Lopes de Faria, J. B.; Lopes de Faria, J. M. Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes, 2009, 58(6), 1382-1390.
63. Wang, H.; Zheng, Z.; Gong, Y.; Zhu, B.; Xu, X. U83836E inhibits retinal neurodegeneration in early-stage streptozotocin-induced diabetic rats. Ophthalmic Res., 2011, 46(1), 19-24.
64. Huang, Y. Z.; McNamara, J. O. Neuroprotective effects of reactive oxygen species mediated by BDNF-independent activation of TrkB. J. Neurosci., 2012, 32(44), 15521-15532.
65. Zong, H.; Ward, M.; Madden, A.; Yong, P. H.; Limb, G. A.; Curtis, T. M.; Stitt, A. W. Hyperglycaemia-induced pro-inflammatory responses by retinal Muller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia, 2010, 53(12), 2656-26566.
66. Berner, A. K.; Brouwers, O.; Pringle, R.; Klaassen, I.; Colhoun, L.; McVicar, C.; Brockbank, S.; Curry, J. W.; Miyata, T.; Brownlee, M.; Schlingemann, R. O.; Schalkwijk, C.; Stitt, A. W. Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia, 2012, 55(3), 845-854.
67. Arnold, E.; Rivera, J. C.; Thebault, S.; Moreno-Paramo, D.; Quiroz-Mercado, H.; Quintanar-Stephano, A.; Binart, N.; Martinez de la Escalera, G.; Clapp, C. High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins. Diabetes, 2010, 59(12), 3192-3197.
68. Hotamisligil, G. S. Inflammation and metabolic disorders. Nature, 2006, 444(7121), 860-867.
69. Odegaard, J. I.; Chawla, A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science, 2013, 339(6116), 172-177.
70. McLeod, D. S.; Lefer, D. J.; Merges, C.; Lutty, G. A. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am. J. Pathol., 1995, 147(3), 642-653.
71. Miyamoto, K.; Khosrof, S.; Bursell, S. E.; Rohan, R.; Murata, T.; Clermont, A. C.; Aiello, L. P.; Ogura, Y.; Adamis, A. P. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc. Natl. Acad. Sci. U. S. A., 1999, 96(19), 10836-10841.
72. Huang, H.; Gandhi, J. K.; Zhong, X.; Wei, Y.; Gong, J.; Duh, E. J.; Vinores, S. A. TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest. Ophth. Vis. Sci., 2011, 52(3), 1336-1344.
73. Zhou, J.; Wang, S.; Xia, X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr. Eye Res., 2012, 37(5), 416-420.
74. Hernandez, C.; Segura, R. M.; Fonollosa, A.; Carrasco, E.; Francisco, G.; Simo, R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet. Med., 2005, 22(6), 719-722.
75. Gustavsson, C.; Agardh, C. D.; Agardh, E. Profile of intraocular tumour necrosis factor-alpha and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy. Acta Ophthalmol. 2012.
76. Zeng, H. Y.; Green, W. R.; Tso, M. O. Microglial activation in human diabetic retinopathy. Arch. Ophthalmol., 2008, 126(2), 227-232.
77. Aguzzi, A.; Barres, B. A.; Bennett, M. L. Microglia: scapegoat, saboteur, or something else? Science, 2013, 339(6116), 156-161.
78. Nwanyanwu, K. H.; Talwar, N.; Gardner, T. W.; Wrobel, J. S.; Herman, W. H.; Stein, J. D. Predicting Development of Proliferative Diabetic Retinopathy. Diabetes Care, 2013.
79. Blandini, F. An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. Funct. Neurol., 2010, 25(2), 65-71.
80. Hu, N. W.; Ondrejcak, T.; Rowan, M. J. Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances. Pharmacol. Biochem. Behav., 2012, 100(4), 855-862.
81. Pulido, J. E.; Pulido, J. S.; Erie, J. C.; Arroyo, J.; Bertram, K.; Lu, M. J.; Shippy, S. A. A role for excitatory amino acids in diabetic eye disease. Exp. Diabetes. Res., 2007, 2007, 36150.
82. Zhang, Y.; Bhavnani, B. R. Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by equine estrogens. B.M.C. Neurosci., 2006, 7, 49.
83. Lieth, E.; Barber, A. J.; Xu, B.; Dice, C.; Ratz, M. J.; Tanase, D.; Strother, J. M. Glial reactivity and impaired glutamate metabolism in short-Term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes, 1998, 47(5), 815-820.
84. Lieth, E.; LaNoue, K. F.; Antonetti, D. A.; Ratz, M. Diabetes reduces glutamate oxidation and glutamine synthesis in the retina. The Penn State Retina Research Group. Exp. Eye Res., 2000, 70(6), 723-730.
85. Li, Q.; Puro, D. G. Diabetes-induced dysfunction of the glutamate transporter in retinal Muller cells. Invest. Ophthalmol. Vis. Sci., 2002, 43(9), 3109-3116.
86. Ambati, J.; Chalam, K. V.; Chawla, D. K.; D'Angio, C. T.; Guillet, E. G.; Rose, S. J.; Vanderlinde, R. E.; Ambati, B. K. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch. Ophthalmol., 1997, 115(9), 1161-1166.
87. Lu, M. J.; Pulido, J. S.; McCannel, C. A.; Pulido, J. E.; Hatfield, R. M.; Dundervill, R. F., 3rd; Shippy, S. A. Detection of elevated signaling amino acids in human diabetic vitreous by rapid capillary electrophoresis. Exp. Diabetes Res., 2007, 2007, 39765.
88. Barnstable, C. J.; Tombran-Tink, J. Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog. Retin. Eye Res., 2004, 23(5), 561-577.
89. Yoshida, Y.; Yamagishi, S.; Matsui, T.; Jinnouchi, Y.; Fukami, K.; Imaizumi, T.; Yamakawa, R. Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab. Res. Rev., 2009, 25(7), 678-686.
90. Shen, X.; Xie, B.; Cheng, Y.; Jiao, Q.; Zhong, Y. Effect of pigment epithelium derived factor on the expression of glutamine synthetase in early phase of experimental diabetic retinopathy. Ocul. Immunol. Inflamm., 2011, 19(4), 246-254.
91. Liu, Y.; Leo, L. F.; McGregor, C.; Grivitishvili, A.; Barnstable, C. J.; Tombran-Tink, J. PEDF peptide eye drops reduce inflammation, cell death, and vascular leakage in diabetic retinopathy in the Ins2akita mice. Mol. Med., 2012.
92. Seki, M.; Tanaka, T.; Nawa, H.; Usui, T.; Fukuchi, T.; Ikeda, K.; Abe, H.; Takei, N. Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes, 2004, 53(9), 2412-2419.
93. Gong, Y.; Chang, Z. P.; Ren, R. T.; Wei, S. H.; Zhou, H. F.; Chen, X. F.; Hou, B. K.; Jin, X.; Zhang, M. N. Protective Effects of Adeno-associated Virus Mediated Brain-derived Neurotrophic Factor Expression on Retinal Ganglion Cells in Diabetic Rats. Cell. Mol. Neurobiol., 2012.
94. Ali, T. K.; Al-Gayyar, M. M.; Matragoon, S.; Pillai, B. A.; Abdelsaid, M. A.; Nussbaum, J. J.; El-Remessy, A. B. Diabetesinduced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury. Diabetologia, 2011, 54(3), 657-668.
95. Kiagiadaki, F.; Savvaki, M.; Thermos, K., Activation of somatostatin receptor (sst 5) protects the rat retina from AMPAinduced neurotoxicity. Neuropharmacology, 2010, 58(1), 297-303.
96. Aizu, Y.; Katayama, H.; Takahama, S.; Hu, J.; Nakagawa, H.; Oyanagi, K. Topical instillation of ciliary neurotrophic factor inhibits retinal degeneration in streptozotocin-induced diabetic rats. Neuroreport, 2003, 14(16), 2067-2071.
97. Ali, T. K.; Matragoon, S.; Pillai, B. A.; Liou, G. I.; El-Remessy, A. B. Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes. Diabetes, 2008, 57(4), 889-898.
98. Ahmed, T.; Yumet, G.; Shumate, M.; Lang, C. H.; Rotwein, P.; Cooney, R. N. Tumor necrosis factor inhibits growth hormonemediated gene expression in hepatocytes. Am. J. Physiol. Gastrointest. Liver. Physiol., 2006, 291(1), G35-44.
99. Wei, Y.; Chen, K.; Whaley-Connell, A. T.; Stump, C. S.; Ibdah, J. A.; Sowers, J. R. Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2008, 294(3), R673-680.
100. The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med., 1993, 329(14), 977-986.
101. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352(9131), 837-853.
102. Gerstein, H. C.; Miller, M. E.; Byington, R. P.; Goff, D. C., Jr.; Bigger, J. T.; Buse, J. B.; Cushman, W. C.; Genuth, S.; Ismail-Beigi, F.; Grimm, R. H., Jr.; Probstfield, J. L.; Simons-Morton, D. G.; Friedewald, W. T. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med., 2008, 358(24), 2545-2559.
103. Lachin, J. M.; Genuth, S.; Nathan, D. M.; Zinman, B.; Rutledge, B. N. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes, 2008, 57(4), 995-1001.
104. Floyd, B.; Chandra, P.; Hall, S.; Phillips, C.; Alema-Mensah, E.; Strayhorn, G.; Ofili, E. O.; Umpierrez, G. E. Comparative analysis of the efficacy of continuous glucose monitoring and selfmonitoring of blood glucose in type 1 diabetes mellitus. J. Diabetes Sci. Technol., 2012, 6(5), 1094-1102.
105. Battelino, T.; Conget, I.; Olsen, B.; Schutz-Fuhrmann, I.; Hommel, E.; Hoogma, R.; Schierloh, U.; Sulli, N.; Bolinder, J. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia, 2012, 55(12), 3155-3162.
106. Breton, M.; Farret, A.; Bruttomesso, D.; Anderson, S.; Magni, L.; Patek, S.; Dalla Man, C.; Place, J.; Demartini, S.; Del Favero, S.; Toffanin, C.; Hughes-Karvetski, C.; Dassau, E.; Zisser, H.; Doyle, F. J., 3rd; De Nicolao, G.; Avogaro, A.; Cobelli, C.; Renard, E.; Kovatchev, B. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes, 2012, 61(9), 2230-2237.
107. Thabit, H.; Hovorka, R. Closed-loop insulin delivery in type 1 diabetes. Endocrinol. Metab. Clin. North. Am., 2012, 41(1), 105-117.
108. Barber, A. J.; Gardner, T. W.; Abcouwer, S. F. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci., 2011, 52(2), 1156-1163.
109. Nakanishi, Y.; Nakamura, M.; Mukuno, H.; Kanamori, A.; Seigel, G. M.; Negi, A. Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogen-activated protein kinase. Exp. Eye Res., 2006, 83(5), 1108-1117.
110. Nakajima, E.; Hammond, K. B.; Rosales, J. L.; Shearer, T. R.; Azuma, M. Calpain, not caspase, is the causative protease for hypoxic damage in cultured monkey retinal cells. Invest. Ophth. Vis. Sci., 2011, 52(10), 7059-7067.
111. Shanab, A. Y.; Nakazawa, T.; Ryu, M.; Tanaka, Y.; Himori, N.; Taguchi, K.; Yasuda, M.; Watanabe, R.; Takano, J.; Saido, T.; Minegishi, N.; Miyata, T.; Abe, T.; Yamamoto, M. Metabolic stress response implicated in diabetic retinopathy: the role of calpain, and the therapeutic impact of calpain inhibitor. Neurobiol. Dis., 2012, 48(3), 556-567.
112. Kusari, J.; Zhou, S.; Padillo, E.; Clarke, K. G.; Gil, D. W. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Invest. Ophth. Vis. Sci., 2007, 48(11), 5152-5159.
113. Koleva-Georgieva, D. N.; Sivkova, N. P.; Terzieva, D. Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy. Folia. Med. (Plovdiv) 2011, 53(2), 44-50.
114. Joussen, A. M.; Poulaki, V.; Mitsiades, N.; Kirchhof, B.; Koizumi, K.; Dohmen, S.; Adamis, A. P. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. Faseb. J., 2002, 16(3), 438-440
115. Joussen, A. M.; Doehmen, S.; Le, M. L.; Koizumi, K.; Radetzky, S.; Krohne, T. U.; Poulaki, V.; Semkova, I.; Kociok, N. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-Term histopathological alterations. Mol. Vis., 2009, 15, 1418-1428.
116. Tsilimbaris, M. K.; Panagiotoglou, T. D.; Charisis, S. K.; Anastasakis, A.; Krikonis, T. S.; Christodoulakis, E. The use of intravitreal etanercept in diabetic macular oedema. Semin. Ophthalmol., 2007, 22(2), 75-79.
117. Wu, L.; Hernandez-Bogantes, E.; Roca, J. A.; Arevalo, J. F.; Barraza, K.; Lasave, A. F. intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina, 2011, 31(2), 298-303.
118. Wang, A. L.; Yu, A. C.; Lau, L. T.; Lee, C.; Wu le, M.; Zhu, X.; Tso, M. O. Minocycline inhibits LPS-induced retinal microglia activation. Neurochem. Int., 2005, 47(1-2), 152-158.
119. Krady, J. K.; Basu, A.; Allen, C. M.; Xu, Y.; LaNoue, K. F.; Gardner, T. W.; Levison, S. W. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes, 2005, 54(5), 1559-1565.
120. Cukras, C. A.; Petrou, P.; Chew, E. Y.; Meyerle, C. B.; Wong, W. T. Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest. Ophth. Vis. Sci., 2012, 53(7), 3865-3874.
121. Powell, E. D.; Field, R. A. Diabetic Retinopathy and Rheumatoid Arthritis. Lancet, 1964, 2(7349), 17-18.
122. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology, 1991, 98(5), 757-865.
123. Zheng, L.; Howell, S. J.; Hatala, D. A.; Huang, K.; Kern, T. S. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes, 2007, 56(2), 337-345.
124. Aiello, L. P.; Davis, M. D.; Girach, A.; Kles, K. A.; Milton, R. C.; Sheetz, M. J.; Vignati, L.; Zhi, X. E. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology, 2006, 113(12), 2221-2230.
125. Titchenell, P. M.; Lin, C. M.; Keil, J. M.; Sundstrom, J. M.; Smith, C. D.; Antonetti, D. A. Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction. Biochem. J., 2012, 446(3), 455-467.
126. Ola, M. S.; Nawaz, M. I.; El-Asrar, A. A.; Abouammoh, M.; Alhomida, A. S. Reduced Levels of Brain Derived Neurotrophic Factor (BDNF) in the Serum of Diabetic Retinopathy Patients and in the Retina of Diabetic Rats. Cell. Mol. Neurobiol., 2012.
127. Misra, G. P.; Singh, R. S.; Aleman, T. S.; Jacobson, S. G.; Gardner, T. W.; Lowe, T. L. Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina. Biomaterials. 2009, 30(33), 6541-6547.
128. Saydah, S. H.; Fradkin, J.; Cowie, C. C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA-J. Am. Med. Assoc., 2004, 291(3), 335-342.
129. Wood, J. R.; Miller, K. M.; Maahs, D. M.; Beck, R. W.; Dimeglio, L. A.; Libman, I. M.; Quinn, M.; Tamborlane, W. V.; Woerner, S. E. Most Youth With Type 1 Diabetes in the T1D Exchange Clinic Registry Do Not Meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines. Diabetes Care, 2013.
130. Ko, F.; Vitale, S.; Chou, C. F.; Cotch, M. F.; Saaddine, J.; Friedman, D. S. Prevalence of nonrefractive visual impairment in US adults and associated risk factors, 1999-2002 and 2005-2008. JAMA-J. Am. Med. Assoc., 2012, 308(22), 2361-2368.
131. Zhang, X.; Saaddine, J. B.; Chou, C. F.; Cotch, M. F.; Cheng, Y. J.; Geiss, L. S.; Gregg, E. W.; Albright, A. L.; Klein, B. E.; Klein, R. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA-J. Am. Med. Assoc., 2010, 304(6), 649-656.
132. Saaddine, J. B.; Honeycutt, A. A.; Narayan, K. M.; Zhang, X.; Klein, R.; Boyle, J. P. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch. Ophthalmol., 2008, 126(12), 1740-1747.